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Atopic diseases such as eczema and asthma are increasingly
prevalent in the western world (1). These complex diseases
are caused by an interplay of genetic and environmental fac-
tors (2). Several prospective studies have shown that eczema
pre-dates or co-exists with asthma (3, 4). Twin studies indi-
cate that these atopic diseases share a common genetic back-
ground, but that also disease-specific genetic factors exist (5).
The chromosomal region 5q31-33 is strongly linked to
eczema (6, 7), asthma and bronchial hyper-responsiveness
(BHR) (8–10). In this region, multiple atopy susceptibility
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Abstract
Background: Eczema and asthma share a common genetic background and show
linkage to chromosome 5q31-33. Protocadherin-1 (PCDH1) is located in this region
and was identified as a susceptibility gene for bronchial hyper-responsiveness
(BHR), a hallmark of asthma. PCDH1 encodes an adhesion molecule, expressed in
airway and skin epithelium. We determined whether PCDH1 polymorphisms, previ-
ously associated with asthma or BHR, also associated with questionnaire and UK
Working Party (UKWP) defined eczema.
Methods: Four PCDH1 polymorphisms were genotyped in two Dutch birth cohorts,
PIAMA (n = 967) and KOALA Birth Cohort Study (n = 1560). Association with
eczema was determined by chi-square tests and generalized estimating equations
(GEE).
Results: Insertion deletion IVS3-116 was associated with development of UKWP
eczema in PIAMA [age 4, OR = 1.90 (1.14–3.18)] and borderline with question-
naire-reported eczema in PIAMA [GEE, OR = 1.33 (0.98–1.81)]. Furthermore,
IVS3-116 was associated with questionnaire-reported eczema in KOALA [age 1,
OR = 1.44 (1.00–2.07)]. Pooled analysis of questionnaire-reported eczema of both
cohorts resulted in a significant association of IVS3-116 with eczema [OR = 1.26
(1.01–1.58)]. Rs3822357 (A-allele) associated with protection for eczema in PIAMA
only [questionnaires, OR = 0.19 (0.06–0.63)].
Conclusion: PCDH1 gene variant IVS3-116 associates with eczema in two indepen-
dent birth cohorts. Combined with previous observations, this indicates a shared
genetic susceptibility to BHR, asthma and eczema.
Abbreviations:
PCDH1, Protocadherin-1; BHR, Bronchial Hyper-responsiveness;
PIAMA, Prevention and Incidence of Asthma and Mite Allergy birth
cohort; KOALA, Dutch acronym for: Child, Parent, health, Focus on
Lifestyle and Predisposition birth cohort; SNP, Single-Nucleotide
Polymorphism; ISAAC, the International Study of Asthma and
Allergies in Childhood; UKWP, UK Working Party criteria; FLG,
Filaggrin; GEE, Generalized Estimating Equations; AD, Atopic
Dermatitis; LD, Linkage Disequilibrium; OR, Odds Ratio; 95% CI,
95% Confidence Interval.
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genes have been identified, such as SPINK5 (eczema), IL-13
(asthma, atopy) and CD14 (atopy). One gene in this region,
Protocadherin-1 (PCDH1), has recently been discovered as a
BHR susceptibility gene (11).
PCDH1 is thought to play a role in cell-cell adhesion (12,
13). PCDH1 mRNA and protein expression were identified
in airway epithelium (11), whereas PCDH1 mRNA is
expressed in skin keratinocytes (14, 15). A defect in epithelial
barrier function may represent an underlying common mech-
anism in asthma, BHR and eczema (16).
We hypothesized that PCDH1 gene variants may represent
a common genetic background of eczema and asthma, owing
to its proposed barrier function in epithelial cells. We there-
fore determined whether SNPs, that were shown previously to
associate with asthma and BHR, are associated with eczema.
To this aim, we investigated the association of PCDH1 SNPs
with eczema in two Dutch prospective birth cohorts.
Material and methods
Study populations
Two Dutch populations were investigated: (i) The Prevention
and Incidence of Asthma and Mite Allergy (PIAMA) birth
cohort and (ii) KOALA (Dutch acronym for: Child, Parent,
health, Focus on Lifestyle and Predisposition) birth cohort.
The local medical ethics committees approved these studies, and
all participants provided written (parental) informed consent.
Ascertainment
Recruitment of subjects for PIAMA birth cohort
Study design of the PIAMA birth cohort has been described
previously (17). In summary, recruitment took place during
the first trimester of pregnancy with a validated screening
questionnaire (18) and was conducted by 52 midwife prac-
tices in three different regions in the Netherlands: north
(Groningen and surroundings), central (Bilthoven and
Wageningen and surroundings) and southwest (Rotterdam
and surroundings). Women reporting any of the following
symptoms were defined as allergic (i.e. a history of asthma,
current hay fever, current allergy to house dust mite or pets),
and their children were defined as ‘high-risk’. A total of
10,232 pregnant women completed the questionnaire and
2949 (29%) of them were ‘allergic’. The participating children
were born between May 1996 and December 1997 and were
followed yearly up to 8 yr of age.
At baseline, the PIAMA study population consisted of
4146 children, 183 (5%) were lost to follow-up. The study
therefore started with 3963 newborns: 1327 children from
allergic mothers and a random sample of 663 children from
non-allergic mothers were selected for medical examinations,
from which 1808 children were eligible for a medical exami-
nation at age 4, and of whom 1288 children participated.
DNA was collected at age 4 from 1037 children during medi-
cal examinations for atopic eczema. Children of non-Dutch
mothers were excluded from the analysis. At the age of 1 yr,
medical examination for eczema was performed only for the
intervention group (n = 414). Intervention consisted of mite-
impermeable mattress covers. Study population characteris-
tics are described in Table 1.
Recruitment of subjects for the KOALA cohort
The design of the study has been described previously (19).
Briefly, participants with diverse lifestyles (conventional and
alternative) were recruited at 34 wk of gestation. Pregnant
women with a conventional lifestyle (n = 2343) were
recruited from an ongoing prospective cohort study on Preg-
nancy-related Pelvic Girdle pain in the Netherlands. Addi-
tionally, pregnant women with an alternative lifestyle
(n = 491) were recruited through organic food shops, anth-
rophosophic doctors and midwifes, Steiner Schools and mag-
azines. During the first 2 yr postpartum, and at the age of
6 yr, information on atopic outcomes and their determinants
were collected for all members of the cohort by repeated
questionnaires at ages 3, 7, 12, 24 months and 6 yr. The
study was approved by the medical ethics committee of the
Maastricht University. Written informed parental consent
was obtained from all participants. All participants were
asked for providing DNA via buccal swaps (n = 1560).
Dutch children were medically examined for atopic eczema at
the age of 2 yr only (n = 676). Characteristics of the study
population are described in Table 1.
Clinical evaluation
Diagnosis of eczema
For the PIAMA cohort at the age of 1–8 yr, and for the
KOALA cohort at 7, 12, 24 months and 6 yr, infants were
defined as having developed eczema if their parents reported
eczema based on ISAAC questions. The ISAAC question-
naire defines eczema as ‘the presence of a history of itchy
rash which was coming and going in the last 12 months,
localized on flexural sites on folds of the elbows, behind the
knees, in front of the ankles, under the buttocks, or around
the neck, ears or eyes. Cases of only diaper rash, rash around
the eyes and/or scalp scaling were excluded.
At home visits at the age of 1 and 4 yr for PIAMA and at
2 yr for KOALA, trained health nurses examined infants for
atopic dermatitis according to the UK Working Party
(UKWP) criteria (20–22) in a subset of the population. In
PIAMA, home visits were performed at 1 yr for children of
the intervention study and at 4 yr for a random sample of
the cohort. In PIAMA, a mandatory modification was made
to the UKWP criteria at 1 yr only, as the UKWP criteria
‘early onset’ and ‘presence of other atopic diseases’ are less
relevant for children at 12 months of age (23).
In KOALA, home visits were performed in children whose
parents gave permission to draw blood samples. Infants with
a UKWP probability score (20) of atopic dermatitis (AD)
>90% were regarded as infants with ‘probable presence of
atopic dermatitis’ as was determined previously (24).
Diagnosis of asthma
In the PIAMA cohort we analysed ‘doctor-diagnosed
asthma’, defined as asthma ever diagnosed by a doctor and
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Number 967 3963 1560 2834
Ethnicity (% Dutch origin) 100 94.2 100 95.8
Boys (%) 51.9 51.8 50.3 51.3
Education level mother (%)
Low 18.3 23.5 8.3 10.7
Intermediate 42.7 41.5 37.3 39.4
High 39.0 35.0 54.4 49.9
Family history (%)
Atopy mother 65.9 31.3 32.9 34.1
Asthma mother 16.3 7.9 8.9 9.3
Atopy father 31.7 30.8 36.6 35.0
Asthma father 7.3 7.7 10.1 10.0
Children at risk (%)* 75.6 51.5 55.8 56.5
Intervention (type) Mattress covers Mattress covers No No
No (%) 57.1 80.7 100 100
Placebo (%) 24.3 10.0 0 0
Active (%) 18.6 9.3 0 0
Environmental exposures
Breast feeding (%)
Never 14.6 17.9 14.6 19.8
<3 months 35.0 38.4 20.7 21.1
‡3 months 50.4 43.7 64.7 59.1
ETS at home first year (%) 22.9 27.8 11.5 15.4
Pet (dog and/or cat) first year (%) 39.6 43.2 39.8 41.9
Dog first year (%) 14.3 16.1 19.8 22.2
Cat first year (%) 29.1 32.8 24.3 23.8
Presence older siblings at birth (%) 48.8 50.5 58.3 55.7
Eczema manifestations
ISAAC questionnaire
1 yr (%) 18.5; n = 174 15.2; n = 559 18.0; n = 263 19.4; n = 484
2 yr (%) 20.1; n = 189 16.6; n = 616 15.4; n = 234 15.3; n = 389
3 yr (%) 22.3; n = 209 17.3; n = 632 N.a. N.a.
4 yr (%) 21.5; n = 200 17.9; n = 631 N.a. N.a.
5 yr (%) 17.9; n = 164 15.3; n = 515 N.a. N.a.
6 yr (%) 18.0; n = 165 15.4; n = 527 13.6; n = 177 13.9; n = 275
7 yr (%) 16.9; n = 150 14.3; n = 479 N.a. N.a.
8 yr (%) 18.3; n = 159 16.0; n = 515 N.a. N.a.
UKWP criteria
1 yr (%) 13.7; n = 56 14.3; n = 479 N.a. N.a.
2 yr (%) N.a. N.a. 13.8; n = 93 13.4; n = 116
4 yr (%) 12.0; n = 115 12.2; n = 155 N.a. N.a.
Total serum IgE
























3 yr (%) 25.3; n = 245 22.9; n = 844 N.a. N.a.
4 yr (%) 24.0; n = 230 18.8; n = 670 N.a. N.a.
5 yr (%) 22.1; n = 211 17.6; n = 615 N.a. N.a.
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asthma present in the last 12 months. Second, we used a defi-
nition of asthma based on symptoms, defined as at least one
attack of wheeze or dyspnoea and/or the prescription of
inhaled corticosteroids in the last 12 months (25). In PIAMA,
bronchial hyper-responsiveness at 8 yr was defined as a fall
of ‡20% in FEV1 after inhalation of a maximum of 0.62 mg
methacholine bromide (26). In the KOALA cohort, asthma
at the age of 6 yr was defined by asthma symptoms: at least
one attack of wheezing or dyspnoea, or regular use of
inhaled asthma medications in the last year.
Genotyping
Subjects from the PIAMA and KOALA cohorts were geno-
typed for three PCDH1 single-nucleotide polymorphisms
(SNPs) (rs3797054, rs3822357 and rs14359) and one insertion
deletion (IVS3-116, Fig. 1a), in amplified DNA by competi-
tive allele-specific PCR using KASPar genotyping chemis-
try, performed under contract by K-Biosciences, as described
previously (27). These polymorphisms were selected based on
previous associations of PCDH1 with BHR and asthma (11).
Linkage disequilibrium (LD) was calculated using Haplo-
view v4.1, by determining D¢ and r2 values (http://
www.broad.mit.edu/mpg/haploview). Genotyping was per-
formed blinded of the clinical status and considered success-
ful when <5% of the genotypes were missing. Furthermore,
all SNPs were tested for deviations from Hardy–Weinberg
equilibrium, using chi-square tests (p > 0.05).
Statistical analysis
Eczema was investigated for association with PCDH1 gene
variants using chi-square tests, comparing genotype frequen-
cies between affected and non-affected individuals. Odds
ratios (OR) and 95% confidence intervals (95% CI) were cal-
culated from logistic regression analysis. To detect a possible
influence of asthma on the associations of PCDH1 with
eczema, analyses were repeated adjusted for asthma.
Generalized estimating equations (GEE) were used to
assess associations between PCDH1 gene variants and the
presence of eczema in the first 8 yr of life. GEE is a longitu-
dinal statistical technique that takes correlations between
repeated measurements in the same individual into account.
As eight observations on atopic dermatitis were made on the
same subject, we performed a GEE analyses to analyse the
relationships of PCDH1 SNPs with eczema simultaneously.
A 7-dependent working correlation structure fitted the data
best. This assumes that the correlations t measurements apart
are equal, the correlations t + 1 measurements apart are
equal and so on for t = 1 to t = 7.
We present the overall estimates based on yearly measure-
ments. We repeated GEE analysis adjusted for parental
atopy, sex, breastfeeding, intervention and study population,
and inspected whether these covariates alter the regression
coefficient ‡10%. In addition, analyses were repeated
adjusted for asthma. We previously investigated and reported
the validity of pooling data from these two highly compara-
ble birth cohorts (27). For all statistical analysis, we report
associations obtained by the best-fitting genetic model.
Results
Genotyping
All tested SNPs were located in or nearby exon 3 of PCDH1.
All SNPs were in Hardy–Weinberg equilibrium (p > 0.05).
The allele frequencies were similar in the PIAMA and
KOALA cohorts (Fig. 1a). Measures of LD were comparable
between study populations. Strong LD was observed for
rs3822357, rs3797054, rs14359 and IVS3-116, as D¢
approaches the value of 1. LD expressed as r2 was remark-
ably lower (0.0–0.17), owing to differences in allele frequen-











6 yr (%) 18.3; n = 174 14.6; n = 507 11.2; n = 146 11.6; n = 228
7 yr (%) 16.6; n = 151 12.3; n = 416 N.a. N.a.
8 yr (%) 17.2; n = 158 13.0; n = 429 N.a. N.a.
Doctor-diagnosed asthma
1 yr (%) 7.2; n = 69 6.1; n = 224 N.a. N.a.
2 yr (%) 5.6; n = 54 4.8; n = 177 N.a. N.a.
3 yr (%) 5.1; n = 49 4.1; n = 152 N.a. N.a.
4 yr (%) 5.2; n = 50 4.1; n = 145 N.a. N.a.
5 yr (%) 5.1; n = 48 4.0; n = 138 N.a. N.a.
6 yr (%) 5.8; n = 55 3.9; n = 134 N.a. N.a.
7 yr (%) 4.2; n = 38 2.8; n = 98 N.a. N.a.
8 yr (%) 5.1; n = 45 3.6; n = 116 N.a. N.a.
Bronchial hyper-responsiveness
8 yr (%) 44.9; n = 293 42.9; n = 402 N.a. N.a.
n, number of samples available; N.a., not available. Definitions of characteristics were described previously (27). *Defined as: children who
have at least one parent with asthma or atopy. Geometric mean (interquartile range).
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Association with eczema in PIAMA and KOALA cohorts
In the PIAMA cohort (see Table 1 for characteristics), the
del IVS3-116 variant was significantly associated with
UKWP-defined eczema at the age of 4 yr, using the best-fit-
ting dominant model [OR = 1.90 (95% CI: 1.14–3.18)], and
a tendency in a similar direction was observed at 1 yr of age
[OR = 1.74 (0.81–3.72)] for this eczema definition. Further-
more, IVS3-116 was border-line associated with increased
risk of eczema, defined by questionnaire, in the PIAMA
cohort [GEE analysis of 0–8 yr; dominant model: OR = 1.33
(0.98–1.81)] (Table 2).
Rs3822357 (A-allele) was significantly associated with
decreased risk of eczema, defined by questionnaire [GEE of
0–8 yr, co-dominant model OR = 0.19 (0.06–0.63)] in the PI-
AMA study. Numbers were too low to accurately determine
association with UKWP criteria.
In the KOALA birth cohort (see Table 1 for characteris-
tics), we also observed an association of IVS3-116 with
increased risk of eczema. IVS3-116 del was significantly asso-
ciated with ISAAC questionnaire–defined eczema at 1 yr
[OR = 1.44 (1.00–2.07), dominant model], but not at later
age and not with UKWP criteria (Table 2). The protective
effect of rs3822357 (A-allele) was not identified in KOALA
(Table 2). Other PCDH1 SNPs were not significantly associ-
ated, neither with ISAAC questionnaire– nor UKWP-defined
eczema, both in PIAMA and KOALA cohorts (data not
shown).
Importantly, GEE analysis on pooled ISAAC question-
naire data of PIAMA and KOALA cohorts resulted in a sig-
nificant association of IVS3-116 with eczema [OR = 1.26
(1.01–1.58), dominant model] (Table 2 and Fig. 2), but not of
rs3822357 [OR = 0.68 (0.23–2.03)]. For IVS3-116, associa-
tions with eczema were specifically identified at age 1 and
3 yr [OR = 1.38 (1.03–1.84) and OR = 1.59 (1.04–2.43)],
and border-line at age 7 yr [OR = 1.60 (0.98–2.60), Fig. 2].
Adjustment for potential confounders (paternal atopy, sex,
breastfeeding, intervention or study population) did not
change any of the earlier mentioned associations.
When we constructed haplotypes using the selected SNPs,
the significant associated deletion variant IVS3-116 was only
in a haplotype with wild type rs14359, rs3797054 and
rs3822357 alleles, with similar allele frequencies as IVS3-116
alone (PIAMA 0.063; KOALA 0.070). Therefore, the haplo-
type analysis did not result in different associations.
As PCDH1 was previously associated with BHR and
asthma, we investigated whether asthma status, at the same
age as when the association of PCDH1 with eczema was
determined, had influence on the association of PCDH1 with
eczema. For the association of UKWP eczema at 4 yr, we
observed no confounding relationship of asthma phenotypes
on the association of PCDH1 with eczema. In addition, cor-
rection for doctor-diagnosed asthma had no influence on the
association analysed by GEE between PCDH1 IVS3-116 and
questionnaire-defined eczema [OR = 1.33 (0.98–1.81),
p = 0.07]. Correction for asthma symptoms even showed a
SNP region name AC094107.3 rs-number Allele 1 Allele 2
Frequency (allele 2) in
cohorts
PIAMA KOALA
1 exon 3 Ala514Thr 77474 rs3822357 G A 0.08 0.07
2 exon 3 Ala750Ala 76764 rs3797054 T C 0.36 0.36
3 exon 3 IVS3 +164 75751 rs14359 G C 0.23 0.23
4 intron 3 IVS3 -116 70270 (submitted) TTC Ins TTC Del 0.06 0.07
gDNA = genomic DNA, SNP = Single Nucleotide Polymorphism, IVS = intervening sequence. Nucleotide
sequence of IVS3_116 is as follows: gaatgtgctgtgctggggcctgggtctctt (-/ctt) ggttgctgttgaagcctgagtaggatggtg.
4321
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Figure 1 Protocadherin-1: Gene,
mRNA expression, SNP position
and LD-pattern. PCDH1 SNPs are
numbered 1–4 and corresponding
minor allele frequencies are calcu-
lated per population (a). Linkage
disequilibrium plots are displayed
for D¢ and R-square values both for
PIAMA and KOALA. D¢ is repre-
sented by gray colour, meaning D¢
is >0.9. r2 = 0 is white and r2 = 1
is represented in black (b).
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small increase in odds ratio [OR = 1.38 (0.99–1.92),
p = 0.058]. Finally, in children with eczema, there was no
significant association of PCDH1 with BHR or asthma at
later age (data not shown).
Discussion
This study showed significant association between the
PCDH1 insertion deletion polymorphism IVS3-116 and
increased risk of eczema, defined by objective measurements
for eczema, the UK Working Party criteria. Moreover, in a
pooled analysis of 2486 children of these birth cohorts, IVS3-
116 was significantly associated with questionnaire-defined
eczema at age 0–8.
We observed association between the PCDH1 polymor-
phism IVS3-116 and eczema in two independent Dutch birth
cohorts. Importantly, the annual ISAAC core questions pro-
vided similar prevalence rates of eczema in these cohorts. We
excluded children from non-Dutch origin and investigated a
homogeneous Dutch population. Our studies were hypothesis
driven, and we therefore did not correct for multiple testing
but rather determined association of PCDH1 polymorphisms
in a second cohort. Furthermore, the same allele (del IVS3-
116) was previously found to be associated with asthma and
BHR (11), providing evidence that these diseases share a
genetic background.
We detected several differences in the pattern of the associ-
ation of PCDH1 with eczema that related to an age-specific
effect, and the association of PCDH1 with eczema defined
through UKWP criteria. For KOALA, data on eczema are
available in the first 2 yr, and IVS3-116 associated with ques-
tionnaire eczema at age 1, but not at 2 or 6 yr, in children
not selected for maternal allergy. This may suggest that
PCDH1 is associated with an early onset of eczema. How-
ever, when analysing PIAMA questionnaire data longitudi-
nally with GEE, no change in risk was observed in time. In
addition, when pooling the questionnaire data of both
cohorts, a significant association was identified during the
whole period in this larger sample size (Fig. 2). Additionally,
Table 2 Associations of PCDH1 SNPs with eczema in PIAMA and KOALA cohorts
Cohort Eczema definition Age (yr) SNP No. total subjects Risk allele Outcome [OR (95%CI)] p-value
PIAMA Questionnaire (GEE Analysis) 0–8 IVS3-116 961 TTC Del (3) 1.33 (0.98–1.81) 0.070
Questionnaire (GEE Analysis) 0–8 rs3822357 961 A (1) 1.16 (0.84–1.61) 0.36
(2) 0.19 (0.06–0.63) 0.0068
UKWP 1 IVS3-116 392 TTC Del (3) 1.74 (0.81–3.72) NS
4 IVS3-116 929 TTC Del (3) 1.90 (1.14–3.18) 0.013
KOALA Questionnaire 1 IVS3-116 1427 TTC Del (3) 1.44 (1.00–2.07) 0.032
2 IVS3-116 1483 TTC Del (3) 0.91 (0.60–1.39) NS
6 IVS3-116 1283 TTC Del (3) 1.10 (0.70–1.72) NS
Questionnaire 1 rs3822357 1438 A (1) 0.75 (0.49–1.15) NS
(2) 0.48 (0.06–3.84) NS
2 rs3822357 1496 A (1) 0.90 (0.59–1.39) NS
(2) 2.32 (0.60–9.05) NS
6 rs3822357 1290 A (1) 0.63 (0.37–1.09) NS
(2) 1.72 (0.35–8.33) NS
UKWP 2 IVS3-116 652 TTC Del (3) 1.00 (0.52–1.92) NS
rs3822357 658 A (1) 0.72 (0.33–1.55) NS
(2) 6.21 (0.86–44.73) NS
Pooled Questionnaire (GEE Analysis) 0–8 IVS3-116 2486 TTC Del (3) 1.26 (1.01–1.58) 0.042
0–8 rs3822357 2486 A (1) 1.03 (0.81–1.31) NS
(2) 0.68 (0.23–2.03) NS
Definition of models: (1) = Heterozygous minor allele compared to homozygous wild type, (2) = Homozygous minor allele compared to
homozygous wild type, (3) = Dominant model (heterozygous and homozygous minor alleles compared to homozygous wild type). NS, not
significant; GEE, generalized estimating equations.
Figure 2 Association of IVS3-116 with eczema in pooled PIAMA
and KOALA cohorts. Results of generalized estimating equations
are shown for IVS3-116. Odds ratios and 95% confidence intervals
are calculated per year for pooled PIAMA and KOALA cohorts,
using a dominant model (*p < 0.05).
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the association of IVS3-116 with eczema was not modified by
paternal allergy.
The association of UKWP eczema with IVS3-116 was
identified at the age of 4 yr in a subset of the PIAMA cohort,
while no association existed in KOALA at age 2 using this
definition. One explanation for the difference in association
of IVS3-116 with UKWP eczema can relate to the slightly
different usage of UKWP criteria. As in KOALA at the age
of 2 yr no data are available on asthma in children, the
UKWP criterion ‘History of asthma or hay fever’ was not
applied, while in PIAMA for the eczema assessment at the
age of 4 yr this criterion was included. This could have led to
an enrichment of children in the PIAMA cohort with asthma
or hay fever, and thereby influence the association. However,
we detected no confounding relationship of asthma on the
association of PCDH1 with eczema. The detected differences
in the associations may relate to the onset or severity of
eczema, or cohort-specific gene–gene or gene–environment
interactions.
Although not strongly replicated, we do observe significant
association in two independent cohorts. The significant asso-
ciations were identified using 115 and 263 eczema subjects
respectively. To investigate replication, we suggest analysing
IVS3-116 in a larger sample size.
We did identify an association of the coding SNP
rs3822357 (Ala514Thr) with eczema in PIAMA. Again, the
same risk allele was observed for BHR in a family study from
the UK and a birth cohort from the US (11). This finding was
not significantly replicated in KOALA. This difference in
association could not be explained by the difference in study
design, as correction for potential confounders (paternal
atopy, sex or breastfeeding) did not alter the association of
rs3822357 with eczema in PIAMA. Given the low allele fre-
quency of the risk allele, power was low to investigate replica-
tion, and we therefore suggest that larger studies have to
analyse this SNP to increase power to detect association.
Three PCDH1 polymorphisms (rs3797054, IVS3-116 and
rs3822357) have been previously reported to associate with
BHR and asthma in Dutch, UK and US populations (11), and
we now report that one of these polymorphisms (IVS3-116) to
be associated with eczema. The functional effects of these gene
variants are not known. Together with the published evidence
on the adhesion function of PCDH1 (13) and its expression in
skin keratinocytes (14), this points towards a role of this gene
affecting epithelial integrity in BHR and asthma, a mechanism
that also has been proposed for eczema (16, 28).
It is of interest to compare our results with data on filag-
grin (FLG), a replicated gene for eczema, resulting in loss of
epithelial integrity in the skin. Previously, we genotyped the
PIAMA cohort for three FLG SNPs, and confirmed the rela-
tive high prevalence of the FLG null mutations in the north
of Europe (29), which clearly differs for Mediterranean popu-
lations, were the frequency of these SNPs was low or not
detected (30). These results point towards genetic heterogene-
ity of this disease. For FLG, we and others have observed an
association with early age at onset of eczema (31–34). In
addition, it has been reported that persons with eczema car-
rying FLG mutations are at increased risk to develop asthma.
Albeit not that strong as for FLG, we do observe significant
associations of relative rare PCDH1 gene variants with
eczema. We were not able to determine FLG and PCDH1
gene–gene interactions owing to low numbers of children car-
riers of both FLG and PCDH1 deletions. Interestingly, for
PCDH1 we did not observe a progression towards asthma at
age 6–8. As the initial genetic association of PCDH1 gene
variants with asthma was identified in an older age group,
longer follow up may be needed to assess progression from
eczema to asthma.
In conclusion, our study provides evidence for the associa-
tion of PCDH1 polymorphism IVS3-116 with eczema. Previ-
ously, IVS3-116 was shown to be associated with BHR. Our
data show that PCDH1 may have a pleiotropic effect on
BHR and eczema in different populations.
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